Last updated: February 25, 2026
What is NDC 60505-0016?
NDC 60505-0016 refers to a specific prescription drug listed in the National Drug Code directory. Based on available data, NDC 60505-0016 corresponds to Voretigene Neparvovec (Luxturna), a gene therapy approved by the U.S. Food and Drug Administration (FDA) in December 2017 for inherited retinal disease caused by RPE65 gene mutations.
Market Overview
Indications and Patient Population
Voretigene Neparvovec addresses a rare hereditary condition affecting approximately 1,000 to 2,000 patients in the U.S. who have confirmed biallelic RPE65 mutation-associated retinal dystrophy (UXRD). Its orphan designation limits direct competition but positions it in a niche market.
Competitive Landscape
- Gene Therapies in Ophthalmology: Luxturna remains the sole approved gene therapy for RPE65-mediated retinal dystrophy.
- Off-label Treatments: No direct gene therapy competitors; standard care involves vitamin A supplementation, mobility aids, and low vision rehabilitation.
- Pipeline Products: Limited RPE65 gene therapies at early development stages, with ongoing clinical trials expanding indications.
Market Dynamics
- Prevalence: 1,000-2,000 patients in the U.S.
- Diagnosis Rate: Estimated underdiagnosis affects market size accuracy.
- Pricing Impact: Given the severity and rarity, high pricing is sustainable with payor reimbursement.
Pricing Analysis
Current Pricing
- List Price: The wholesale acquisition cost (WAC) for Luxturna in the U.S. is approximately $425,000 per eye.
- Total Cost: For bilateral treatment, the total price nears $850,000 per patient.
- Reimbursement: Managed through a combination of private insurance, Medicaid, and Medicare, with coverage often negotiated based on cost-effectiveness analyses and clinical benefit.
Cost Components
- Manufacturing: High due to complex vector production.
- Administration: Intravitreal injections require specialized ophthalmological procedures.
- Post-Treatment Care: Includes clinical follow-ups and visual assessments.
Price Trends and Projections
| Year |
Price per Treatment |
Notes |
| 2017 |
$425,000 |
Launch price at FDA approval |
| 2020 |
$425,000 |
No major price changes reported |
| 2023 |
$425,000 |
Maintains initial launch price |
| 2025 |
Projected |
Potential price adjustments driven by manufacturing efficiencies or market entry of competitors |
Given the lack of direct competition, the price has remained stable over recent years. Future price adjustments are unlikely unless the manufacturing process reduces costs or new therapies enter the market.
Market Volume and Revenue Projections
Market Penetration Assumptions
- Year 1 (2023): 150 treated patients (estimated 15% of addressable population)
- Year 3 (2025): 300 patients, assuming increased awareness and diagnosis rates
- Year 5 (2027): 500 patients, sustained growth, potential expansion to other retinal conditions
Revenue Estimates
| Year |
Patients Treated |
Price per Patient |
Estimated Revenue |
| 2023 |
150 |
$425,000 |
$63.75 million |
| 2024 |
200 |
$425,000 |
$85 million |
| 2025 |
300 |
$425,000 |
$127.5 million |
| 2026 |
400 |
$425,000 |
$170 million |
| 2027 |
500 |
$425,000 |
$212.5 million |
Long-term Outlook
Potential expansion to other rare retinal disorders or broader indications could increase patient volume. However, the current market remains narrowly confined due to the specific genetic mutation requirement.
Regulatory and Policy Factors
- Reimbursement Coverage: Critical for market access; negotiation with payors is required to optimize reimbursement.
- Pricing Reforms: Future policy moves toward value-based pricing may influence pricing strategies.
- Manufacturing Costs: Advances in vector production could reduce costs, enabling lower prices.
Key Takeaways
- NDC 60505-0016 (Luxturna) operates in a niche, with approximately 1,000-2,000 eligible patients in the U.S.
- The current list price stands at $425,000 per eye; bilateral treatment totals about $850,000.
- Market revenues are projected to reach over $200 million annually by 2027, assuming gradual patient volume growth.
- Pricing stability is expected unless manufacturing efficiencies lower costs or new entrants emerge.
- Significant policy and reimbursement factors will influence future market access and pricing strategies.
FAQs
Q1: How likely is price reduction for Luxturna in the next five years?
A1: Price reductions are unlikely unless manufacturing costs decrease significantly or policy reforms pressure drug prices.
Q2: Can the patient volume grow beyond current estimates?
A2: Yes, if diagnosis rates improve and the therapy expands to broader conditions or broader age groups.
Q3: Are there competitors to Luxturna?
A3: Currently, no direct competitors. Pipeline therapies are in early clinical stages, but none have FDA approval yet.
Q4: How does the pricing compare to other gene therapies?
A4: Luxturna's price is high but comparable to other gene therapies in rare diseases, which can range from $400,000 to over $2 million.
Q5: What factors could impact reimbursement coverage?
A5: Evidence of clinical benefit, cost-effectiveness ratios, and payer policies. Payers increasingly focus on value-based assessments.
References:
[1] U.S. Food and Drug Administration. (2017). FDA approves innovative gene therapy to treat certain rare inherited retinal diseases. https://www.fda.gov/news-events/press-announcements/fda-approves-innovative-gene-therapy-treat-certain-rare-inherited-retinal-diseases
[2] IQVIA. (2023). Prescription drug price trends. IQVIA Institute.
[3] EvaluatePharma. (2023). World Preview of Pharma Market Trends. Evaluating the Future of Pharma R&D.
